Supplementary Figure 1 from Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer

Key Points

• Molecular characterization reveals mechanisms of acquired resistance to KRAS G12C–EGFR inhibition.
• In vitro models show how colorectal cancer adapts and survives against targeted therapies.
• Various acquired resistance mechanisms were identified, including alterations in signaling pathways.
• Understanding these mechanisms is crucial for developing more effective colorectal cancer treatments.